Teva has announced that the US FDA has approved its tobramycin inhalation solution, a generic equivalent to Novartis’s TOBI inhalation solution for the treatment of P. aeruginosa infections in cystic fibrosis patients. According to Teva, the company will launch the product in November 2013 in accordance with an agreement with Novartis.
Read the Teva press release.
published on
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
